2025-05-17 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data, formatted as requested.

## JNJ Stock Analysis (May 20, 2025)

**0. Executive Summary:**

Johnson & Johnson (JNJ), a global healthcare giant, underperformed the S&P 500 significantly in the examined period. Recent performance shows mixed signals, with recent price increases but negative long-term return expectations.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** JNJ
*   **Company:** Johnson & Johnson - A global healthcare company focused on pharmaceuticals, medical devices, and consumer health products.
*   **JNJ Cumulative Return:** 18.84%
*   **VOO Cumulative Return:** 84.12%
*   **Absolute Divergence:** -65.28%
*   **Relative Divergence:** 11.8% (This indicates that JNJ's underperformance is currently near the lower end of its historical range relative to VOO.)

**Analysis:** JNJ has significantly underperformed the S&P 500 over the analyzed period. The relative divergence of 11.8% suggests that this underperformance, while substantial, is not unprecedented historically.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
| ---------- | ------- | ------- | ------- | ----- | ------ |
| 2015-2017  | 28.0%   | 56.0%   | -1.0%   | 0.0   | 274.9  |
| 2016-2018  | 10.0%   | 10.8%   | -7.0%   | 0.0   | 260.8  |
| 2017-2019  | 20.0%   | 10.8%   | -9.0%   | 0.7   | 303.1  |
| 2018-2020  | 14.0%   | 59.8%   | -12.0%  | 0.5   | 335.9  |
| 2019-2021  | 28.0%   | 59.9%   | -26.0%  | 0.3   | 374.3  |
| 2020-2022  | 4.0%    | 61.2%   | -2.0%   | 0.3   | 396.7  |
| 2021-2023  | -19.0%  | 61.2%   | -35.0%  | 0.4   | 362.6  |
| 2022-2024  | -31.0%  | 61.2%   | -47.0%  | 0.3   | 345.2  |
| 2023-2025  | -7.0%   | 70.8%   | -39.0%  | 0.2   | 364.1  |

**Analysis:**

*   **Alpha:** JNJ consistently displays negative alpha, indicating underperformance relative to the benchmark (S&P 500). This suggests JNJ has not been generating excess returns compared to what would be expected based on its beta.
*   **Beta:** JNJ has a low beta, generally ranging from 0.0 to 0.7, indicating lower volatility compared to the market. This suggests JNJ is less sensitive to market movements.
*   **CAGR:** The compound annual growth rate (CAGR) varies significantly over the periods, with some periods showing strong growth but more recent periods showing negative growth.
*   **MDD:** The maximum drawdown (MDD) indicates the largest peak-to-trough decline during the period. High MDD values suggest significant potential losses, especially in recent periods.
*   **Cap(B):** Market capitalization in billions of dollars.

**2. Recent Price Action**

*   **Current Price:** $151.33
*   **Previous Close:** $149.61
*   **Change:** +1.15%
*   **5-day Moving Average:** $149.98
*   **20-day Moving Average:** $154.21
*   **60-day Moving Average:** $158.49

**Analysis:** The stock price is currently above the 5-day moving average, but below the 20-day and 60-day moving averages. The recent price increase suggests short-term positive momentum, but the longer-term moving averages indicate a potential downtrend.

**3. Market Risk Indicators**

*   **Market Risk Indicator (MRI):** 0.3475 (Low Risk)
*   **RSI:** 41.91 (Neutral)
*   **PPO:** -0.33 (Bearish)
*   **20-day Relative Divergence Change:** -13.9 (Short-term decline in relative performance)
*   **Expected Return:** -227.5% (Significant underperformance vs. S&P 500 expected over a long-term investment horizon)

**Analysis:**

*   The MRI suggests a low-risk environment.
*   The RSI is near the oversold level, potentially indicating a buying opportunity.
*   The negative PPO confirms the short-term downtrend.
*   The large negative expected return is a major concern, suggesting significant long-term underperformance relative to the S&P 500 if the trend continues.
*   The price change of +1.15% from the previous close indicates a notable upward movement, possibly in reaction to recent news or market sentiment.

**4. Recent News & Significant Events:**

*   **May 16, 2025:** JNJ faces major business developments, regulatory changes, or market events.
*   **May 13, 2025:** Analysts discuss JNJ's performance within industry trends and global economic factors.
*   **May 17, 2025:** JNJ stock shows notable volatility.
*   **May 15, 2025:** Market experts highlight both risks and opportunities, advising monitoring of recent news.

**Analysis:** Recent news suggests a dynamic environment for JNJ, with potential regulatory impacts and market volatility. Investor sentiment may be influenced by these factors.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue     |
| ---------- | ---- | ----------- |
| 2025-04-23 | 4.57 | $21.89B     |
| 2024-10-23 | 1.12 | $22.47B     |
| 2024-07-25 | 1.95 | $22.45B     |
| 2024-05-01 | 1.35 | $21.38B     |
| 2025-04-23 | 1.35 | $21.38B     |

**Analysis:** The EPS and revenue figures vary, but the most recent EPS is significantly higher than previous quarters, which could be a positive sign. Revenue appears relatively stable.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
| ------------ | ----------- | ------------- |
| 2025-03-31   | $21.89B     | 66.40%        |
| 2024-12-31   | $22.52B     | 68.35%        |
| 2024-09-30   | $22.47B     | 69.01%        |
| 2024-06-30   | $22.45B     | 69.40%        |
| 2024-03-31   | $21.38B     | 69.55%        |

**Analysis:** The profit margin has decreased slightly over the observed period, which may be a concern.

**Capital and Profitability:**

| Quarter      | Equity      | ROE         |
| ------------ | ----------- | ----------- |
| 2025-03-31   | $78.11B     | 14.08%      |
| 2024-12-31   | $71.49B     | 4.80%       |
| 2024-09-30   | $70.16B     | 3.84%       |
| 2024-06-30   | $71.54B     | 6.55%       |
| 2024-03-31   | $70.02B     | 4.65%       |

**Analysis:** ROE (Return on Equity) shows significant variability, with a recent increase. This increase could be due to the higher EPS reported in the most recent earnings analysis.

**7. Overall Analysis and Summary**

Johnson & Johnson (JNJ) exhibits the following key characteristics:

*   **Underperformance:** Significant underperformance compared to the S&P 500.
*   **Low Volatility:** Lower beta indicates stability compared to the broader market.
*   **Mixed Signals:** Recent price increase contradicts negative long-term return expectations.
*   **Financial Health:** Declining profit margins need monitoring despite increasing equity and recent ROE.
*   **News Impact:** Recent news and events suggest the company is undergoing significant changes, contributing to market volatility.
*   **Earnings Variability:** Recent earnings figures show volatile EPS and more stable revenue.

**Investment Recommendation:** Given the historical underperformance, negative expected returns, and potential market volatility, a **cautious approach** is warranted. Investors should carefully monitor JNJ's financial performance, news developments, and consider the overall market environment before making investment decisions. The recent increase in the stock price does not negate the significant long-term underperformance.

